Immune restoration with interleukin-2 in patients with squamous cell carcinoma of the head and neck
Autor: | Timothy R. Jones, Robert W. Cantrell, Ronald C. Pace, Paul A. Levine, Harold J. Wanebo |
---|---|
Rok vydání: | 1989 |
Předmět: |
Adult
Interleukin 2 Lymphocyte medicine.medical_treatment chemical and pharmacologic phenomena Lymphocyte proliferation Lymphocyte Activation Immune tolerance Immune system Immune Tolerance Humans Medicine Phytohemagglutinins Aged Aged 80 and over Immunity Cellular business.industry Head and neck cancer General Medicine Middle Aged medicine.disease Head and neck squamous-cell carcinoma Killer Cells Natural medicine.anatomical_structure Cytokine Head and Neck Neoplasms Immunology Carcinoma Squamous Cell Interleukin-2 Surgery business medicine.drug |
Zdroj: | The American Journal of Surgery. 158:356-360 |
ISSN: | 0002-9610 |
DOI: | 10.1016/0002-9610(89)90133-5 |
Popis: | Patients with head and neck squamous cell carcinoma commonly have depressed cell-mediated immunity which is known to correlate with ultimate prognosis. Selective immune studies were conducted in 27 head and neck cancer patients to determine the potential of interleukin-2 as an immune restorative agent. Patients showed the expected depression of lymphocyte proliferation to phytohemagglutinin and had borderline depressed natural killer cell activity and relatively normal interleukin-2 production. Addition of interleukin-2 at 100 units/ml markedly enhanced natural killer cell activity to normal levels. Serum from head and neck patients was also immune-suppressive. Heat-inactivated serum depressed lymphocyte proliferation and natural killer cell activity of control leukocytes. Lymphocyte incubation with interleukin-2 significantly counteracted immune suppressive serum effects and restored depressed lymphocyte function to normal levels. The effective in vitro interleukin-2 dose is potentially achievable by infusion at approximate doses of 3 X 10(6) units/M2. |
Databáze: | OpenAIRE |
Externí odkaz: |